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Cationic polymers are widely used as materials to condense nucleic acids for gene-based therapies.
These have been developed to mainly deliver DNA and RNA for cancer therapies but the ongoing
COVID-19 pandemic has demonstrated an urgent need for new DNA and RNA vaccines. Given this, suit-
able manufacturing conditions for such cationic polymers which can protect the nucleic acid in the for-
mulation and delivery stages but release the cargo in the correct cellular compartment effectively and
safely are required. A number of polymers based on poly(amidoamine)s fit these criteria but their synth-
eses can be time-consuming, inefficient and poorly reproducible, precluding their adoption as manufac-
turable vaccine excipients. Here we report an improved synthesis of poly(cystamine bisacrylamide-co-4-
amino-1-butanol), abbreviated as pABOL, via modifications in concentration, reaction time and reaction
conditions. Optimisation of monomer contents and stoichiometries, solvents, diluents and temperature,
combined with the application of microwaves, enabled the preparation of vaccine candidate pABOL
materials in 4 h compared to 48 h reported for previous syntheses. These procedures were highly repro-
ducible in multiple repeat syntheses. Transfection experiments with a model RNA showed that polymers
of formulation with appropriate molar masses and mass distributions were as effective in model cell lines
as polymers derived from the unoptimised syntheses which have been shown to have high efficacy as
RNA vaccine formulation candidates.
Introduction
The application of polycations in the formulation of nucleic
acid delivery systems has accelerated rapidly in recent years.1–4
Advances in gene editing technologies, and the possibilities
for DNA- and RNA-based therapies and vaccines against
cancers and infectious diseases, have all contributed to the
focus on polycation-based gene delivery formulations.5–9
Within the large field of cationic polymers, materials based on
oligo- or poly(amidoamine)s (pAMAMs) and poly
(β-aminoesters) (pBAEs) have been extensively
investigated.10–16 This is because these polymers are intrinsi-
cally biodegradable and can be synthesised from a range of
commercially available bisacrylamide/bisacrylates (for
pAMAMs/pBAEs respectively) and primary amines, thus
enabling high chemical diversity and consequent broad utility
across different nucleic acid delivery platforms.17 pAMAMs in
particular have shown particular promise due to their limited
mid-chain hydrolysis and higher water solubility due to their
amide backbone, in comparison to esters in pBAEs. However,
while the preparation of pAMAMs is relatively straight-forward
for research investigations,18 in the case of rapid manufacture
potentially required for high volume nucleic acid vaccine pro-
duction, the current synthetic protocols are sub-optimal. In
particular, there is a pressing need to understand if methods
used for the preparation of pAMAMs can be tuned to produce
materials with the right properties for delivery of mRNA or
other nucleic acid vaccine candidates in a reproducible way,
and in a manner which might allow for rapid and distributed
manufacture.
Accordingly, the aim of the study presented here was to
investigate the synthetic parameters leading to reproducible
and faster synthesis of a specific class of pAMAMs, whilst
potentially making the procedure more amenable to micro-
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wave acceleration and continuous flow technologies for scale
up and potential decentralised manufacture. The specific
focus was to develop a more rapid synthesis of poly(cystamine
bisacrylamide-co-4-amino-1-butanol), hereinafter referred to as
pABOL, which has shown promise as a highly efficient delivery
vector for self-amplifying RNA (saRNA) in candidate vaccine
formulations.19 Pioneering work on this polymer,20 and
related materials,21–24 initially established broad efficacy
across a range of gene delivery applications, with the bioredu-
cible disulfide linker greatly enhancing the expression of trans-
genes and minimising vector toxicity.25 In most reports, the
synthesis of pABOL is conducted via the step-growth Michael-
addition polymerisation between N,N′-cystaminebisacrylamide
and 4-amino-1-butanol, either without solvent, or in high con-
centrations in apolar solvents. These methods typically allow
the generation of polymers with molar masses of 103–104 g
mol−1 and Đ values above 2, but reactions under these con-
ditions require several days to reach high molar masses. The
demand for sufficient cationic polymer for many millions of
vaccine doses to be made rapidly available is incompatible
with reactions which take long time periods. There is now a
requirement to develop methods by which pABOL-type poly-
mers can be produced to an appropriate specification for
reproducible vaccine formulations in a minimum time frame.
Accelerated polymerisations, may also be relevant in structure–
property optimisation studies to screen structural (molar mass,
branching etc.) and chemical (lipophilicity, basicity, charge
density etc.). However, the current slow synthetic methods for
this family of polymers significantly hinders structure optimi-
sation, potentially useful for tailoring polymer vectors to an
emerging nucleic acid vaccine candidate.
We report here a synthetic optimisation study, screening
the effect of reaction parameters such as inert atmospheres,
monomer concentration, reactant ratio and reaction tempera-
ture on the molecular weight distribution of pABOL. Through
these improvements, we were able to minimise a radical
branching side reaction, then accelerate the prevailing step-
growth polymerisation with microwave assisted synthesis. The
conditions established in this work were highly reproducible
in comparison to unoptimized conditions. Finally, we high-
light the importance of controlling the molecular weight distri-
bution by evaluating the correlation of certain polymer
physicochemical characteristics and their propensity to effec-
tively deliver a model saRNA vaccine.
Experimental
Materials
All solvents were of analytic or HPLC grade and purchased
from Sigma Aldrich or Fisher Scientific unless otherwise
stated. All deuterated solvents were purchased from Sigma
Aldrich. Reagents 4-aminobutanol (178330-5G), N,N′-bis(acry-
loyl)cystamine (A4929-5G) and triethylamine were purchased
from Sigma-Aldrich. fLuc VEEV saRNA (9382 nt) was prepared
as described previously.26
Instrumentation
1H NMR spectroscopy. 1H NMR, spectra were recorded at
25 °C on a Bruker Advance III 400 MHz spectrometer. All
chemical shifts are reported in ppm (δ) referenced to the
chemical shifts of residual solvent resonances of d6-DMSO
(2.50 ppm). MestReNova 6.0.2 copyright 2009 (Mestrelab
Research S. L.) was used for analysing the spectra.
Size exclusion chromatography. A Polymer Laboratories
PL-50 instrument equipped with differential refractive index
(DRI), viscometry (VS) and dual angle light scatter (LS) was
used for SEC analysis. The system was fitted with 2 × PLgel
Mixed D columns (300 × 7.5 mm) and a PLgel 5 µm guard
column. The eluent used was DMF with 0.1% LiBr. Samples
were run at 1 ml min−1 at 50 °C. Poly(methyl methacrylate)
standards (Agilent EasyVials) were used for calibration
between 955 500–550 g mol−1. Analyte samples were filtered
through a membrane with 0.22 μm pore size before injection.
Respectively, experimental molar mass (Mn,SEC) and dispersity
(Đ) values of synthesized polymers were determined by conven-
tional calibration using Cirrus GPC software.
Polymer synthesis
General procedure for synthesis of pABOL. pABOL was syn-
thesised via the following general procedure, the unoptimised
procedure is detailed here. In a typical experiment, CBA, ABOL
and triethylamine were added into a test tube charged with a
stir bar and the reagents suspended in a MeOH/water mixture
(4/1, v/v) and the tube sealed with a rubber septum.
Polymerization was carried out in the dark at 45 °C under a
static nitrogen atmosphere. Polymers utilised in transfection
studies were isolated using the following procedure: the result-
ing solution was diluted with MeOH (50 mL), acidified with 1
M HCl to pH ∼ 4, and then purified by dialysis with acidic
water (4.0 L, pH ∼ 5, refreshed 6 times in 3 days). The poly-
mers in their HCl-salt form were collected as white solid after
lyophilisation.
Formulation of saRNA polyplexes
Stock solutions of pABOLs and saRNA were prepared first by
directly dissolving these materials in molecular grade water
and stored at 4 °C for up to 3 months. The concentrations of
the stock solutions are 0.24 μg μL−1 (fLuc VEEV saRNA), and
5.00 μg μL−1 (pABOLs) respectively.
In vitro transfection of saRNA polyplexes
Transfections were performed in HEK293T.17 cells (ATCC,
USA) that were maintained in culture in complete Dulbecco’s
Modified Eagle’s Medium (cDMEM) (Gibco, ThermoFisher,
UK) containing 10% (v/v) fetal calf serum (FCS), 5 mg mL−1
L-glutamine and 5 mg mL−1 penicillin and streptomycin
(ThermoFisher, UK). Cells were plated at a density of 50 000
cells per well in a 96 well plate 24 h prior to transfection. At
the time of transfection, the media was completely removed
and replaced by 50 µL of transfection media (DMEM with
5 mg mL−1 L-glutamine). 100 µL of the polyplex solution was
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added to each well and incubated for 4 h. Then, the media was
replaced with cDMEM and the cells were allowed to culture for
24 hours, at which time 50 µL of media was removed and
50 µL of ONE-Glo™ D-luciferin substrate (Promega, UK) was
added and mixed well by pipetting. The total volume was
transferred to a white 96-well plate (Costar, UK) and analyzed
on a FLUOstar Omega plate reader (BMG LABTECH, UK).
Results and discussion
Previous reports of the synthesis of pABOL have utilised proto-
cols where N,N′-bis(acryloyl)cystamine (CBA), 4-aminobutanol
(ABOL) and triethylamine in a methanol/water are mixed and
heated with stirring at 45 °C under a nitrogen atmosphere for
up to 14 days.19 We thus commenced our studies by following
this synthesis (Fig. 1) and observed a clear viscous solution at
the end of two weeks heating at 45 °C (Table 1, entry 1). NMR
spectra (Fig. 1B) and DMF-SEC revealed successful polymeris-
ation, with an Mw,SEC = 45 kg mol
−1 and a relatively broad
molecular weight distribution (Đ = 3.62). The origins of this
high Đ appeared to be due to an additional high molecular
weight peak in the chromatogram, which was postulated to be
caused by chain branching through a side reaction of radical
polymerisation (Fig. 1C).
These results suggest that the high reaction concentration
(3.2 M) and inert conditions both favour this side reaction. We
thus conducted a systematic study, varying the reaction con-
ditions to mitigate this side reaction. Previous data indicated
that pABOL of Mw ∼ 8 kg mol−1 yields high saRNA transfection
in animal models. Therefore, throughout the optimisation
study we targeted polymers around this molecular weight.
Systematic optimisation of polymerisation
Effect of dilution and inert conditions. Radical polymeris-
ations are favoured under inert conditions (oxygen is known to
act as a radical scavenger), further exacerbated at high
monomer concentrations.27,28 We therefore evaluated the
molecular weight evolution over 2 weeks for the step-growth
polymerisation at a ∼5-fold dilution (0.6 M instead of 3.2 M)
under inert (argon deoxygenated) compared to a polymeris-
ation under air (oxygenated) to limit the radical polymerisation
side reaction.
Immediately comparing the argon deoxygenated conditions
at lower dilution (Table 1, entry 2), we observed a steady
increase in molar mass without the appearance of a bimodal
high molar mass peak. A high molar mass shoulder however,
was observed after 10 d in the SEC chromatograms, indicating
some radical polymerisation was still occurring at diluted
deoxygenated conditions (Fig. 2A). This was further evidenced
by the minimal increase in Mn,SEC whilst Mw,SEC continued to
climb after this time point. Noticeably, the diluted conditions
appear to retard the side reaction, however, do not completely
Fig. 1 (A) Synthetic scheme for step-growth Michael-addition polymerisation of N,N’-cystaminebisacrylamide and 4-amino-1-butanol to produce
pABOL, (B) 1H NMR spectrum of pABOL; (C) size exclusion chromatogram of product obtained via ‘conventional’ synthesis.
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Table 1 Polymerisation conditions for pABOL syntheses reported in this study
Description Entry [ABOL] (M) [CBA] (M) [ABOL]/[CBA] Atmosphere T (°C)
Original 1 3.2 3.2 1 Argon 45
Dilution 2 0.60 0.60 1 Argon 45
Dilution + air 3 0.60 0.60 1 Air 45
Temperature 4 0.60 0.60 1 Air 60
5 0.60 0.60 1 Air 25
[M] 6 3.2 3.2 1 Air 60
7 0.8 0.8 1 Air 60
8 0.45 0.45 1 Air 60
9 0.24 0.24 1 Air 60
Monomer ratio 10 0.60 0.60 1 Air 60
11 0.606 0.60 1.01 Air 60
12 0.615 0.60 1.025 Air 60
13 0.63 0.60 1.05 Air 60
14 0.66 0.60 1.1 Air 60
15 0.72 0.60 1.2 Air 60
Repeatability 16 0.60 0.60 1 Air 60
17 3.2 3.2 1 Argon 45
Microwave 18 0.60 0.60 1 Air 100
Fig. 2 (A and C) DMF-SEC chromatograms and (B and D) molecular weight evolution of pABOL at [M] = 0.60 M, T = 45 °C polymerisation in an
argon or air atmosphere. (E) Evolution of dispersity over time for pABOL. (F) Schematic representation of step-growth polymerisation and subsequent
radical polymerisation leading to branching under inert conditions and inhibition of radical polymerisation under air.
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inhibit it. Comparatively at the 10 d time point under air
(Table 1, entry 3), no further increase in molecular weight was
observed, likely due to the radical scavenging mechanism of
oxygen (Fig. 2B). This is further exemplified in the Đ values,
with samples taken from polymerisations performed under air
maintaining Đ < 1.6, while Đ for polymers prepared under
inert atmosphere rose to ∼4.5 over the 2 weeks reaction
(Fig. 2C).
We anticipate that the steadily increasing high molar mass
shoulder was a result of successive branching events, other-
wise inhibited under an air atmosphere (Fig. 2D). The diluted
conditions significantly slowed the rate of polymerisations
taking 96 h to reach Mw,SEC > 8 kg mol
−1, whilst concentrated
conditions (5-fold higher concentration), reached these molar
masses within 48 h.
Effect of temperature and microwave acceleration. One of
the other parameters which may affect the rate of this branch-
ing mechanism, even under oxygenated conditions, is temp-
erature. We compared polymerisations performed at 60 °C
(Table 1, entry 4) (close to the boiling point of methanol
solvent) and 25 °C (Table 1, entry 5), compared to the previous
results obtained at 45 °C (Table 1, entry 3), monitoring mole-
cular weight evolution daily for 96 h. As expected, we observed
significantly faster growth in molecular weight at the higher
temperatures, with reactions performed at 60 °C plateauing
within 48 h at Mw ∼ 10 kg mol−1. Lower temperatures slowed
the polymerisation significantly, only reaching ∼3 kg mol−1
within 96 h (Fig. 3A and C). Notably, although still under a
higher dilution, polymerisations at 60 °C reached the target
8 kg mol−1 within 48 h, the same timeframe as the concen-
trated conditions at 45 °C. Importantly no evidence of branch-
ing was observed even at the 96 h timepoint, 2 d after the poly-
merisation terminated. Overall, higher temperatures did not
induce more branching, but did increase the rate of polymeris-
ation sufficiently to compensate for the diluted conditions.
With these conditions providing low viscosity solutions and
exhibiting minimal side reactions we sought to accelerate
further the synthetic procedure utilising microwave irradiation.
Microwave accelerated synthesis has two major advantages:
firstly, microwaves homogenously heat solvents, leading to
reliable heat gradients; secondly most microwave synthesis
procedures occur under high pressure conditions, increasing
the boiling point of solvent.29,30 These effects both synergise
and enable synthesis at significantly higher temperatures and
faster reaction rates than conventional heating. Furthermore,
microwave accelerated synthesis is highly amenable to continu-
ous flow reactors as they offer fast, but energy efficient syn-
thetic routes to scalable manufacture, important in rapid
response supply chains.31
To evaluate pABOL synthesis using microwave assisted
heating, we utilised a Biotage microwave synthesiser set to 200
W, heating to 100 °C and monitored the molecular weight evol-
ution over 24 h (Table 1, entry 18). Under these conditions, we
observed a significantly faster increase in molecular weight,
reaching ∼8 kDa in ∼4 h rather than 48 h, a 12-fold accelera-
tion compared to conventional heating at 60 °C (Fig. 3B and
C). Chromatograms were comparable under microwave con-
ditions and conventional, with similar Đ regardless of heating
method.
Effect of monomer concentration and ratio. Having pre-
viously observed that the polymerisation plateaus without
branching under oxygenated conditions, we postulated that
Fig. 3 (A and B) DMF-SEC chromatograms and (C) molecular weight evolution of pABOL at [M] = 0.60 M and air atmosphere at 25 °C, 45 °C and
60 °C under conventional heating at 100 °C under using microwave assisted heating.
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the molecular weight at which this termination takes place
may be controlled in a concentration dependent manner. It is
well established that as step-growth polymerisations ensue,
higher concentrations help overcome steric effects which limit
chain-chain addition steps.32 To probe this, we performed
polymerisations at 4 concentrations and monitored the evol-
ution of molecular weight daily over 72 h. A solution of the
original conditions was aliquotted equally into 4 tubes, and
each diluted with the methanol/H2O mixture such that they
were at 3.2 M (no extra solvent), 0.8 M, 0.45 M and 0.24 M
(Table 1, entries 6–9) and heated to 60 °C under air. For the
lower three concentrations we observed that the polymeris-
ation terminated after 48 h, but achieving lower molecular
weights for lower polymerisation concentrations (Fig. 4A and
B). At the highest concentration, we observed that after 72 h, a
high molar mass shoulder appeared potentially indicating
some branching may occur even at high concentrations in an
air atmosphere.
To achieve high molar masses for step-growth polymeris-
ations it is imperative to have a near equimolar ratio between
the A and B components. However, if the ratios are not per-
fectly equimolar (i.e. 1–10% out), it is possible to tune the
molecular weight and end-group of the final polymers. We pre-
pared 5 polymerisations at an equimolar ratio and added 1%,
2.5%, 5%, 10% and 20% (Table 1, entries 11–15) excess ABOL
and heated the tubes for 48 h at 60 °C under an air atmo-
sphere. With 1% extra ABOL we observed no difference in final
Mw, compared to the purely equimolar polymerisation,
however with higher amounts of excess ABOL a decreasing
trend in Mw with increasing excess ABOL was evident (Fig. 4C
and D). At 20% excess ABOL, no polymerisation or only oligo-
merisation was observed. This data also provides important
information on the weighing/stoichiometric error allowed
(max. 1%) to avoid molecular weight discrepancy.
Repeatability. The optimised conditions ([M] = 0.60 M, T =
60 °C, air atmosphere) yielded a low viscosity solution, with
minimal branching observed in SEC chromatograms. We
therefore studied the repeatability of the conditions, preparing
3 independent reactions for the optimised (Table 1, 3 × entry
16) and original conditions (Table 1, 3 × entry 17). After 48 h at
60 °C under an air atmosphere, the polymerisations were
stopped and the molecular weight measured via DMF-SEC.
The three polymerisations performed under the ‘new’ con-
ditions had almost identical chromatograms, with an average
Mw = 9100 ± 610 g mol
−1 and Đ = 1.31 ± 0.00. In contrast, poly-
merisations with the ‘old’ conditions exhibited an average Mw
= 16 700 ± 5500 g mol−1 and Đ = 3.51 ± 1.07 (Fig. 5A–C). The
variation in Mw and Đ for the ‘old’ conditions is most likely a
consequence of the bimodal distribution, absent in the ‘new’
conditions. Overall, the new conditions presented here gener-
ated polymers with more reproducible properties.
Effect of polymer properties on biological activity. In view of
the potential applications of pABOL in gene delivery,19 and
specifically in the need for rapid deployment as components
in nucleic acid vaccine formulations, we evaluated pABOLs,
P1-P6, synthesised by a range of conditions for efficacy in
transfection (Fig. 6A and B). These experiments were carried
out to assess how the spread of molar masses, polydispersities
and other chromatogram features (e.g. unimodal vs. bimodal
molecular weight distributions) of polymers made under
Fig. 4 (A) DMF-SEC chromatograms and (B) molecular weight evolution of ABOL + CBA polymerisations at 60 °C and an air atmosphere at [M] =
3.2, 0.8, 0.45 and 0.24 M. (C) DMF-SEC chromatograms and (D) Mw,SEC of final polymers after 48 h reaction between CBA and ABOL at different
ABOL/CBA ratios. Reactions were performed at 60 °C and an air atmosphere at [M] = 0.60 M.
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different conditions might alter RNA vaccine expression. For
these studies we utilised luciferase encoding self-amplifying
RNA (saRNA) as a model vaccine. The length of this model
saRNA (9382 nt) is in accordance with vaccine constructs e.g.
SARS-CoV-2 saRNA is 11 551 nt.33 saRNA constructs have
shown great promise in vaccine applications, as their manufac-
ture can be conducted in vitro in a pathogen agnostic manner
but can achieve similar efficacy and protective immunity at
1000-fold lower doses than conventional mRNA.34–36
There were marked differences in saRNA expression deli-
vered by the various polyplexes derived from the synthesised
polymers, dependent on molecular weight distribution
(Fig. 6A). Three polymers (P2, P3 and P6) displayed lower luci-
ferase expression (∼101 RLU), whilst the other three exhibited
up to 5 orders of magnitude higher luminescence. Comparing
the molecular weight distributions of these two groups
(Table S8†), it was clear that polymers with bimodal distri-
butions and thus high Đ severely reduces saRNA transfection.
Overall, these results indicate transfection efficiency is signifi-
cantly enhanced using polymers with monomodal distri-
butions, highlighting the need to minimise radical induced
branching as shown in this study. The key question for future
development of these materials is therefore what the best com-
promise between speed and reliability of synthetic method is,
while retaining effective transfection in a vaccine setting
in vivo.
Conclusions
In conclusion, we have optimised the A2 + B2 step-growth poly-
merisation between CBA and ABOL, yielding conditions that
provide low viscosity solutions and minimal side reactions.
Our findings suggest that at high concentrations the radical
branching side reaction is relatively favourable, with dilution
this is partially retarded but is completely inhibited under an
air atmosphere. The optimised conditions are now highly
reproducible and the timeframe to achieve the 8 kg mol−1
target can be accelerated using a microwave synthesiser. These
conditions and accelerated timeframe make this synthesis
more amenable to scale up, particularly in continuous flow. In
terms of the future rapid manufacture of vaccines, the pro-
cesses to produce these materials are robust, and show small
batch-batch variability even with low durations of synthesis.
Furthermore, the use of microwaves and simple conditions
will facilitate the transfer to flow chemistries, further enhan-
cing the suitability of this method for rapid and scalable man-
ufacture of vaccine excipients. These microwave conditions,
utilising standardized equipment, may also provide a reliable
method for reproducible decentralized batch synthesis, useful
in disease outbreak scenarios where traditional supply chains
are constrained. Given the chemical versatility of pAMAM cat-
ionic polymer platform, through variation of the two com-
ponents, we anticipate the findings will extend to synthesis
processes with other amines and bisacrylamides. To date we
do not yet know the optimal set of physicochemical character-
Fig. 5 (A and B) DMF-SEC chromatograms and (C) Mw of final polymers
after 48 h reaction between CBA and ABOL performed in triplicate.
Reactions were performed at 60 °C, [M] = 0.60 M and an air atmosphere
compared to 45 °C, [M] = 3.2 M and an argon atmosphere.
Fig. 6 (A) Transfection of polyplexes with saRNA encoding luciferase at
N/P = 45 in HEK 293T.17 cells 24 h after treatment. (B) GPC chromato-
grams of polymers used in transfection studies.
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istics which produce the best saRNA vaccine properties in vivo,
and the correlation between in vitro and in vivo efficacy
remains challenging. Nevertheless, the data presented here
provide indicators towards more rapid and scalable synthesis
of promising nucleic acid vaccine formulation components.
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